Dr. Adrian Kinkaid, CEO

Adrian has extensive experience in the life sciences sector, with particular expertise in affinity reagents, including antibodies, affimers and aptamers. He has developed a thorough understanding of the field and considers MIPs as a cost effective and high quality alternative to existing reagents due especially to their robustness and speed of development.

Prior to joining MIP Diagnostics, Adrian worked as Chief Commercial Officer for Promexus, a protein biotherapeutics company based on affimer technology from Avacta Life Sciences. Before this he was Head of Technology Access and then Strategic Market Development Leader for Abcam, the leading provider of research antibodies.

Adrian’s industrial experience started with agrochemical and pharmaceutical discovery where he developed a range of different biochemical and cell based assays mainly for high throughput screening applications. Adrian is also a Founding Member of ELRIG (European Laboratory Research and Innovation Group) a not-for-profit organisation that holds conferences and events for thought leadership in the life science and drug discovery communities. Adrian served two terms as Chairman, during which time he established the flagship Drug Discovery event, which is now the leading conference of its kind in Europe.

Jim Reid, Chairman

Jim has worked in the life sciences sector for the past 40 years, holding senior roles within key firms including Axis-Shield PLC, Chiron S.A, Roche and Trinity Biotech Inc. Since 2000, he has managed ChimaeraBio, a specialist life sciences investment fund which he founded with Karen Reid. He has also been involved with a number of Scotland’s more successful life science companies, including Haptogen (acquired by Wyeth), Qnostics (acquired by BBI plc) and D3 Technologies (acquired by Renishaw plc). Jim was also Chairman at Lumora upon its very successful exit in 2015.

Prof. Sergey Piletsky, Founder

A leading expert on Molecularly Imprinted Polymers (MIPs) and biosensors Sergey Piletsky is a Professor of Bioanalytical Chemistry at University of Leicester and Head of Leicester Biotechnology Group.

Having developed new methods for the automated synthesis of MIP nanoparticles compatible with industrial manufacturing processes, Sergey championed the creation of MIP Diagnostics Ltd in order to commercialise this remarkable technology. MIPs are stable to extremes of temperature, pH, pressure and organic solvents and therefore much more robust than their biological counterparts (antibodies, enzymes etc.). MIPs have applications in diagnostics (sensors and assays), in separations, in catalysis and as biologically active species. Sergey's expertise has been built up over 25 years, and maintained through links with numerous companies from across the globe, engaged in the manufacture of diagnostic devices and polymers. His group has modern state-of-art facilities required for polymer research including computational modules, a range of HPLC, HPLC-MS-MS, NMR, ESR, AFM, and other analytical instruments and sensor platforms such as conductometric, electrochemical, QCM and optical (Biacore 3000).

Prof. Piletsky supervised work of numerous MSc and PhD students and published over 270 peer-reviewed papers and patent applications. Prof. Piletsky is Visiting Professor in Jinan and Huazhong Universities, China, Toulon University, France, member of Editorial Board of ACS Combinatorial Sciences, Scientific Board of Society of Molecular Imprinting, Fellow of the Society of Biology, Secretary General of the International Union of Advanced Materials.

Dr. Antonio Guerreiro, Director of Technology & Founder

Dr. Antonio Guerreiro, one of our founders, has recently joined MIP Diagnostics leaving the University of Leicester where he was a Research Fellow in Chemical Engineering in the Chemistry Department since 2013. His research interests focused mainly on de novo design of functional polymers with molecular recognition properties to be used as a replacement for antibodies.

Antonio completed his PhD at Cranfield University in 2006, after obtaining his MEng in Biotechnology at the University of Algarve in Portugal. In his thesis work he pioneered several techniques for the preparation of molecularly imprinted nanoparticles which would later lead to the invention and development of the solid-phase imprinting method. After finishing his PhD, he worked on the development of biosensors and polymeric adsorbents based on imprinted and rationally designed polymers. Part of this work included the design of new flow-processes for the manufacture of imprinted nanomaterials. This eventually culminated in the development of the solid-phase imprinting method, for which he shares the original patent with Prof. Sergey Piletsky, at the time at Cranfield University.  In 2013, and with the intention of expanding the range of research and applications of imprinted materials into the biological/biomedical field, he joined the University of Leicester. There, together with Prof. Piletsky and with support from the Mercia, they founded MIP Diagnostics Ltd.

Francesco Canfarotta, Senior Scentist

Francesco received his M.S. degree in Pharmaceutical Chemistry and Technology from the University of Palermo (Italy) in 2010 and his PhD from University of Leicester (UK) in 2016. During his academic studies, he worked on the synthesis of polymeric micelles for drug delivery applications. Afterwards, he worked as a pharmacist for 6 months and then he joined Cranfield University in 2011 as Marie Curie research fellow. In 2014, he then moved to the University of Leicester, where he completed his PhD research in molecularly imprinted polymer nanoparticles for diagnostic applications, including fluorescent and multifunctional nanosystems based on optical detection and cell biocompatibility studies.